Therapeutic HPV vaccine Phase Ib trial completes recruitment; H5N1 vaccine into Phase III in Vietnam;

> Vietnamese researchers have moved an H5N1 vaccine into Phase III studies, after positive results from Phase I and II trials. Blog post

> Protein Sciences has granted Merck ($MRK) a non-exclusive license to its expresSF+ serum-free insect cell line for vaccine research. Press release

> A University of Alberta researcher has discovered a potential hepatitis C vaccine; there is currently no vaccine available. Press release

> French biopharma company Genticel has completed recruitment of a Phase Ib trial of ProCervix, its therapeutic HPV vaccine designed for women already infected with the virus. Press release

> Increased use of pneumococcal vaccines in children seems to have cut levels of invasive pneumococcal disease in people with HIV. Abstract

> The International AIDS Vaccine Initiative (IAVI) has awarded $875,000 in grants to two researchers identified through NineSigma's Open Innovation process. Press release

> Novartis Vaccines and Diagnostics has withdrawn its application to the European Medicines Agency for a pediatric marketing authorization for Fluad Paediatric (influenza vaccine). Press release

And Finally… Chagas' disease vaccine for pets could prevent spread of the disease to humans. Press release

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.